Coloplast Group Due Diligence
Run due diligence on Coloplast Group: check compliance and get alerts when suppliers or ownership change.
Denmark · owned by Independent (Denmark) · coloplast.com · 20 vendors
Coloplast creates intimate healthcare solutions for people with ostomy, continence, wound care, and other medical needs. The company helps over 2 million people annually across 100+ countries with products including ostomy bags, catheters, wound dressings, and surgical implants.
Resilience scores
- Digital Sovereignty: 20
- Digital Resilience: 8
- Financial Resilience: 9
Technology vendors
- Omada A/S — Technology — Denmark
- ServiceNow, Inc. — Technology — United States
- Workday, Inc. — Other — United States
- and 17 more
Services catalogue
1 service in catalogue across 1 category; runs on 20 sub-vendors.
- Personal Data Processing
Insights
Last updated 2026-09-13 · revision 2
20 direct vendors, 229 subvendors
Direct vendors by controlling owner country (sample)
- Japan: 1
- Australia: 1
- Denmark: 2
Subvendors by controlling owner country (sample)
- Poland: 3
- Spain: 1
- Belgium: 2
Financials
Three-year financials
- 2023: revenue 24535000000, EBIT 7210000000, equity 12504000000
- 2022: revenue 22602000000, EBIT 6861000000, equity 12109000000
- 2021: revenue 19845000000, EBIT 6134000000, equity 11530000000
Financial Resilience Score: 9/10
Coloplast's core products are essential for users with chronic medical conditions. This creates a highly stable and predictable demand, making the company exceptionally resilient to economic downturns. Customers cannot easily postpone or forgo purchasing these products. An EBIT margin consistently near 30% is best-in-class within the MedTech industry. This provides a substantial buffer to absorb cost inflation or fund strategic investments without compromising financial stability. Coloplast has historically maintained a strong balance sheet with a low net debt-to-EBITDA ratio. This conservative capital structure provides significant financial flexibility for M&A, R&D investment, and shareholder returns (dividends). The company holds #1 or #2 market share positions globally in its key business areas of Ostomy Care and Continence Care. This market dominance creates a significant competitive moat, reinforcing its pricing power and long-term stability. While heavily weighted towards Europe, the company has a strong and growing presence in North America and other developed markets, which mitigates risk from any single economy.
Key strengths: Non-Discretionary Product Portfolio, High and Stable Profitability, Strong Balance Sheet & Low Leverage, Market Leadership, Geographic Diversification
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.